BR112023018619A2 - Inibidores de heteroaril de calicreína plasmática - Google Patents

Inibidores de heteroaril de calicreína plasmática

Info

Publication number
BR112023018619A2
BR112023018619A2 BR112023018619A BR112023018619A BR112023018619A2 BR 112023018619 A2 BR112023018619 A2 BR 112023018619A2 BR 112023018619 A BR112023018619 A BR 112023018619A BR 112023018619 A BR112023018619 A BR 112023018619A BR 112023018619 A2 BR112023018619 A2 BR 112023018619A2
Authority
BR
Brazil
Prior art keywords
plasma
kalykrein
inhibitors
heteroaryl
heteroaryl inhibitors
Prior art date
Application number
BR112023018619A
Other languages
English (en)
Inventor
Alastair Rae
Mark Travins Jeremy
Mark Ellard John
Andrew Spencer Jonathan
Nikolaos Papaioannou
Stuart Laurie Chapman Robert
Jocelyn Fink Sarah
Shane Rankin Stuart
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112023018619A2 publication Critical patent/BR112023018619A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

inibidores de heteroaril de calicreína plasmática. a presente invenção fornece compostos e composições dos mesmos que são úteis como inibidores de calicreína plasmática e que exibem características desejáveis para os mesmos.
BR112023018619A 2021-03-17 2022-03-16 Inibidores de heteroaril de calicreína plasmática BR112023018619A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163162468P 2021-03-17 2021-03-17
PCT/US2022/020482 WO2022197758A1 (en) 2021-03-17 2022-03-16 Heteroaryl inhibitors of plasma kallikrein

Publications (1)

Publication Number Publication Date
BR112023018619A2 true BR112023018619A2 (pt) 2023-11-28

Family

ID=81328275

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018619A BR112023018619A2 (pt) 2021-03-17 2022-03-16 Inibidores de heteroaril de calicreína plasmática

Country Status (10)

Country Link
US (1) US20240228488A1 (pt)
EP (1) EP4308230A1 (pt)
JP (1) JP2024516073A (pt)
KR (1) KR20240004296A (pt)
CN (1) CN117355521A (pt)
AU (1) AU2022240596A1 (pt)
BR (1) BR112023018619A2 (pt)
CA (1) CA3208243A1 (pt)
MX (1) MX2023011014A (pt)
WO (1) WO2022197758A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
JP2022549601A (ja) 2019-09-18 2022-11-28 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
WO2024064214A2 (en) * 2022-09-21 2024-03-28 Takeda Pharmaceutical Company Limited Synthesis of cyclopropane carboxylic acids
CN117069662A (zh) * 2023-10-17 2023-11-17 峰成医药科技(天津)有限公司 一种4,6-二氯-2-（二氟甲基）嘧啶的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof

Also Published As

Publication number Publication date
JP2024516073A (ja) 2024-04-12
MX2023011014A (es) 2023-12-06
CA3208243A1 (en) 2022-09-22
CN117355521A (zh) 2024-01-05
WO2022197758A1 (en) 2022-09-22
EP4308230A1 (en) 2024-01-24
US20240228488A1 (en) 2024-07-11
AU2022240596A1 (en) 2023-10-19
KR20240004296A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
BR112023018619A2 (pt) Inibidores de heteroaril de calicreína plasmática
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
BR112018006034A2 (pt) compostos bicíclicos como inibidores de atx
BR112018006080A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MX2018006288A (es) Inhibidores de acc tipo ester y usos de los mismos.
CO2018004750A2 (es) Composiciones para inhibir la actividad arginasa
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
CA3010752A1 (en) Inhibitors of the pd-1/pd-l1 protein/protein interaction
BR112017023710A2 (pt) inibidores de histona deacetilase e composições e métodos de uso dos mesmos
BR112017026682A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
NZ721217A (en) Biaryl inhibitors of bruton’s tyrosine kinase
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
BR112022022608A2 (pt) Compostos como inibidores de bcl-2
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
BR112022017727A2 (pt) Inibidores de eif4e e usos dos mesmos
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
BR112012032884A2 (pt) compostos e composições heteroarílicos como inibidores de quinase proteica
CO2022007621A2 (es) Nuevos inhibidores de braf como rompedores de la paradoja
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos